GlassScriptPhysician profile
Navid Bouzari
NPI 1417168535
$4,631.18
in general payments reported to CMS, 2019-2025
23 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $102 · 2021: $244 · 2022: $796 · 2023: $613 · 2024: $789 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,698 · Grant: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.83 |
| Grant | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.18 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $784.47 | 2019-2025 | Tremfya, Stelara, Simponi |
| Amgen INC. | $497.86 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $364.96 | 2019-2025 | |
| Lilly USA, LLC | $317.69 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Regeneron Healthcare Solutions, INC. | $312.19 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $240.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $207.74 | 2022-2025 | Sotyktu |
| Ucb, INC. | $179.94 | 2021-2025 | Bimzelx |
| Pfizer INC. | $172.54 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $159.38 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Leo Pharma INC. | $123.07 | 2019-2025 | Adbry, Anzupgo |
| Celgene Corporation | $61.29 | 2019 | |
| Incyte Corporation | $55.32 | 2022-2023 | Opzelura |
| Allergan, INC. | $50.40 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $44.52 | 2023-2024 | Puraply, Cygnus Dual |
| Mimedx Group, INC. | $41.36 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.26 | 2025 | Spevigo |
| Galderma Laboratories, L.P. | $29.68 | 2022-2025 | Nemluvio |
| Blueprint Medicines Corporation | $29.39 | 2022 | |
| Arcutis Biotherapeutics, INC. | $24.98 | 2024 | Zoryve |
| Almirall LLC | $16.24 | 2019 | |
| Merck Sharp & Dohme LLC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Bouzari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.